anifrolumab
anifrolumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Systemic Lupus Erythematosus、Cardiovascular Disease、Premature Atherosclerosis、Lupus Erythematosus, Systemic。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
19 项
全球在招研究
8 项
已进入 III/IV 期
37 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- AstraZeneca
- University of Pisa
- Tongji Hospital
- Aurinia Pharmaceuticals Inc.
- National and Kapodistrian University of Athens
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
丹麦、法国、德国、西班牙、美国、加拿大、意大利、Mexico、Poland、中国台湾、Argentina、澳大利亚
正在招募患者的 anifrolumab 研究
Anifrolumab Malignancy and Serious Infections Study
不适用招募中丹麦法国德国西班牙NCT07000110NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
不适用招募中德国NCT07424261A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
III 期招募中美国加拿大法国德国NCT07430306Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
III 期招募中美国Argentina澳大利亚奥地利NCT07691970Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
IV 期招募中美国NCT06594068Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
不适用招募中意大利NCT07330245Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients
不适用招募中意大利NCT07215754The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
II 期招募中美国NCT05440422Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
IV 期招募中中国NCT07077486Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
不适用招募中美国NCT06659029A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
II 期招募中澳大利亚比利时ChileIsraelNCT07630714INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
不适用招募中Argentina中国Costa RicaEgyptNCT06314282PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
IV 期招募中美国NCT07611214An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
III 期招募中美国ArgentinaBrazil加拿大NCT05835310Anifrolumab Pregnancy Study
不适用招募中美国NCT07049653A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus
III 期招募中中国NCT07751848Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)
II 期招募中GreeceNCT07584083The Anifrolumab PRIM Program
不适用招募中瑞典NCT06795893A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
III 期招募中美国Argentina澳大利亚奥地利NCT06455449
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。